MetLife Investment Management LLC Purchases Shares of 5,710 Rapport Therapeutics (NASDAQ:RAPP)

MetLife Investment Management LLC acquired a new position in shares of Rapport Therapeutics (NASDAQ:RAPP) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 5,710 shares of the company’s stock, valued at approximately $117,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Values First Advisors Inc. acquired a new stake in Rapport Therapeutics during the third quarter worth $31,000. BNP Paribas Financial Markets acquired a new stake in shares of Rapport Therapeutics during the 3rd quarter valued at about $34,000. SG Americas Securities LLC bought a new stake in Rapport Therapeutics in the third quarter valued at about $101,000. Sandia Investment Management LP acquired a new position in Rapport Therapeutics in the second quarter worth about $116,000. Finally, Davidson Kempner Capital Management LP acquired a new position in Rapport Therapeutics in the second quarter worth about $229,000.

Rapport Therapeutics Stock Performance

NASDAQ RAPP opened at $20.53 on Tuesday. Rapport Therapeutics has a 1-year low of $16.55 and a 1-year high of $29.74. The firm’s 50 day moving average is $23.17.

Rapport Therapeutics Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.